ACE Inhibitors, Angiotensin Receptor Blockers, Mineralocorticoid Receptor Antagonists, and Renin Antagonists

Therapy in Nephrology & Hypertension

Volumn , Issue , 2008, Pages 601-609

  Hollenberg, Norman K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856115976     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605484-9.50054-X     Document Type: Chapter

References (62)

1. Burnier M, Brunner HR Angiotensin II receptor antagonists. Lancet 2000, 355:637-645.
2. Epstein M, Williams G, Weinberger M, et al. for the Heart Outcome Prevention Evaluation (HOPE) Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. New Engl J Med 2000, 342:145-153.
3. Hollenberg NK, Fisher NDL, Price DA Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32:387-392.
4. Nickerson M, Hollenberg NK Blockade of alpha-adrenergic receptors. Physiological Pharmacology 1967, 243-305. Academic Press, New York. W. Root (Ed.).
5. Ruddy MC, Kostis JB Angiotensin II receptor antagonist. Hypertension: A Companion to Brenner and Rector-s The Kidney 1999, 621-637. WB Saunders, Philadelphia. S. Oparil, M.A. Weber (Eds.).
6. Perich RB, Jackson B, Rogerson FM, et al. Two binding sites on angiotensin converting enzyme: Evidence from radioligand binding studies. Molecular Pharmacol 1992, 42:286-293.
7. Wei L, Alhenc-Gelas F, Corvol P, Clauser E The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 1991, 266:9002-9008.
8. Ehlers MRW, Riordan JF Angiotensin-converting enzyme: Zinc and inhibitor binding stoichiometries of the somatic and testis isozymes. Biochemistry 1991, 30:7118-7126.
9. Wei L, Clauser E, Alhenc-Gelas F, Corvol P The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992, 267:13398-13405.
10. Perich RB, Jackson B, Attwood MR, et al. Angiotensin-converting enzyme inhibitors act at two different binding sites on angiotensin-converting enzyme. Pharma Pharmacol Let 1991, 1:41-43.
11. Sica DA, Todd W, Gehr B Angiotensin-converting enzyme inhibitors. Hypertension: A Companion to Brenner and Rector-s The Kidney 1999, 599-609. WB Saunders, Philadelphia. S. Oparil, M. Weber (Eds.).
12. Wilcox CS Management of hypertension in patients with renal disease. Cardiovascular Therapeutics: A Companion to Braunwald-s Heart Disease 1996, 538-545. WB Saunders, Philadelphia. T.W. Smith (Ed.).
13. Furakawa Y, Kishimoto S, Nishikawa K: Hypotensive imidazole derivatives and hypotensive imidazole 5-acetic acid derivatives. Patents issued to Takeda Chemical Industries, Ltd., on 20 July 1982, and 19 October 1992, respectively. U.S. Patents 4,340,598 and 4,355,040, Osaka, Japan, 1982 and 1992.
14. Wexler RR, Greenlee WJ, Irvin JD, et al. Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy. J Med Chem 1996, 39:626-656.
15. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin antagonists. IX: Pharmacology of EXP-3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990, 255:211-217.
16. Keenan RM, Weinstock J, Finkelstein JA, et al. Potent nonpeptide angiotensin II receptor antagonists. 1-(carboxybenzyl)imidazole-5-acrylic acids. J Med Chem 1993, 36:1880-1892.
17. Edwards RM, Aiyar N, Ohlstein EH, et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992, 260:175-181.
18. 1 receptor antagonists. Angiotensin II Receptor Antagonists 2001, 105-118. Hanley & Belfus, Philadelphia. M. Epstein, H.R. Brunner (Eds.).
19. 1 receptor blockers. Angiotensin II Receptor Antagonists 2001, 189-214. Hanley & Belfus, Philadelphia. M. Epstein, H.R. Brunner (Eds.).
20. Hollenberg NK Arthur C. Corcoran Lecture. Implications of species difference for clinical investigation: Studies on the renin-angiotensin system. Hypertension 2000, 35:150-154.
21. Azizi M, Webb R, Nussberger J, Hollenberg NK Renin inhibition with aliskiren: Where are we now, and where are we going?. J Hypertension 2006, 24:243-256.
22. Staessen JA, Yan L, Richart T Oral renin inhibitors. Lancet 2006, 368:1449-1456.
23. Tice CM Renin inhibitors. Ann Rep Med Chem 2006, 41:155-167.
24. Nguyen G, Burckle CA, Sraer J-D Renin/prorenin-receptor biochemistry and functional significance. Curr Htn Reports 2004, 6:129-132.
25. Danser AH, Batenburg WW, van Esch JHM Prorenin and the (pro)renin receptor-an update. Nephrol Dial Transplant 2007, 22:1288-1292.
26. Fisher NDL, Hollenberg NK: Unprecedented renal responses to direct blockade of the renin-angiotensin system with Aliskiren, a novel renin inhibitor. Circulation 2008, in press.
27. Lewis EJ, Hunsicker LG, Bain RP The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462. Rohde RD for the Collaborative Study Group.
28. Lansang MC, Hollenberg NK ACE inhibition and the kidney: Species variation in the mechanisms responsible for the renal hemodynamic response. JRAAS 2000, 1:119-124.
29. Giatras I, Lau J, Levey AS, Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta analysis of randomized trials. Ann Intern Med 1997, 127:337-345.
30. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. Collaborative Study Group.
31. Parving H-H, Lehnert H, Brochner-Mortensen J, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
32. Brenner BM, Cooper ME, DeZeeuw D, RENAAL Study Investigators, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
33. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Major outcomes in high risk hypertensive patients randomized to Angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002, 288:2981-2997.
34. Casas JP, Chua W, Loukageorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes. Systematic review and meta-analysis. Lancet 2005, 366:2026-2033.
35. Suissa S, Hutchinson T, Brophy JM, Kezouh A ACE inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006, 69:913-919.
36. Hollenberg NK, Epstein M Renin angiotensin system blockade and nephropathy: Why is it being called into question, and should it be?. Clin J Am Soc Nephrol 2006, 1:1046-1048.
37. Hollenberg NK Is there a pharmacologic basis for combination renin axis blockade?. Kidney Int 2005, 68:2901-2903.
38. Hollenberg NK Omission of drug dose information [Letter]. Arch Intern Med 2006, 166:368.
39. Rahman M, Pressel SL, Davis BR Reply to letter to the editor: Omission of drug dose information. Arch Intern Med 2006, 166:368-369.
40. Hollenberg NK, Raij L Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993, 153:2426-2435.
41. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. Kidney Int 2000, 58:2084-2092.
42. Brilla CG, Weber KT Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
43. Greene EL, Kren S, Hostetter TH Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063-1068.
44. Rocha R, Stier CT, Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
45. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators [See Comments]. N Engl J Med 1999, 341:709-717.
46. Epstein M, Williams G, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. CJASN 2006, 1:940-951.
47. Del Vecchio L, Procaccio M, Vigano S, Cusi D Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Nature Clin Pract Nephrol 2007, 3:42-49.
48. Overdiek JWPM, Merkus FWHM Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986, 40:531.
49. Shackelton CR, Wong NLM, Sutton RAL Distal (potassium-sparing) diuretics. Diuretics, Physiology, Pharmacology and Clinical Use 1986, 117-134. WB Saunders, Philadelphia. J.H. Dirks, R.A.L. Sutton (Eds.).
50. Schrijver G, Weinberger MH Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979, 25:33-49.
51. Greenblatt DJ, Koch-Weser J Adverse reactions to spironolactone: A report from the Boston Collaborative Drug Surveillance Program. JAMA 1973, 225:40-43.
52. Roos JC, Mees EJ Dorhout, Koomans HA, Boer P Intrarenal sodium handling during chronic spironolactone treatment. Nephron 1984, 38:226-232.
53. Fernandez-Juarez G, Barrio V, de Vinuesa SG, et al. Dual blockade of the renin-angiotensin system in the progression of renal disease: The need for more clinical trials. J Am Soc Nephrol Suppl 2006, 17:250-254.
54. Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria responses to high-dose valsartan in type 2 diabetes mellitus. J Hypertension 2007, 25:1921-1926.
55. Azizi M, Webb R, Nussberger J, Hollenberg NK Renin inhibition with aliskiren: Where are we now, and where are we going?. J Hypertension 2006, 24:243-256.
56. Beckerman B Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. CJASN 2006, 1:940-951.
57. Burnier M, Brunner HR Angiotensin II receptor antagonists. Lancet 2000, 355:637-645.
58. Danser AH, Batenburg WW, van Esch JHM Prorenin and the (pro)renin receptor-an update. Nephrol Dial Transplant 2007, 22:1288-1292.
59. Epstein M, Williams G, Weinberger M, et al. for The Heart Outcome Prevention Evaluation (HOPE) Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. New Engl J Med 2000, 342:145-153.
60. Hollenberg NK, Epstein M Renin Angiotensin system blockade and nephropathy: Why is it being called into question, and should it be?. Clin J Am Soc Nephrol 2006, 1:1046-1048.
61. Hollenberg NK, Fisher NDL, Price DA Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32:387-392.
62. Navar LG, Harrison-Bernard LM, Imig JD, Mitchell KD Renal actions of angiotensin II and AT 1 receptor blockers. Angiotensin II Receptor Antagonists 2001, 189-214. Hanley & Belfus, Philadelphia. M. Epstein, H.R. Brunner (Eds.).